Alberta 2025: Inside AGLC’s THC Potency Audit—Common Failures and How to Fix Them

Alberta’s regulated market has a reputation for speed and competition, but it also has one of the most active post-market oversight environments in Canada. Since 2020, Alberta Gaming, Liquor and Cannabis (AGLC) has been running a secondary testing program that pulls products from the Alberta supply chain for third-party laboratory analysis—using a mix of random sampling and complaint-driven sampling. Publicly shared updates in 2025 reinforced a key theme: most compliance breakdowns are not driven by contamination findings, but by potency variance and labelling issues—a signal that many suppliers still have gaps in lot-level QA/QC and label substantiation.

This post explains what the AGLC THC potency audit 2025 trend means for Alberta suppliers, brands, and retailers—and how to build a defensible “potency truth” program that will survive random sampling.

Informational only. This is not legal advice.

What AGLC’s potency audit really is (and why it matters)

AGLC has confirmed it sends a handful of product samples each quarter to independent labs for testing based on random sampling and complaints (program operating since 2020). Industry coverage of AGLC’s updates notes that suppliers have received notices tied to labelled THC levels and that potency issues—especially for dried flower—can be persistent and difficult to manage without tight controls.

Even if your product passed pre-market release testing, a post-market sample can fail for reasons that include:

• lot-to-lot variability
• within-lot sampling variance (especially with flower)
• method differences (instrumentation, extraction efficiency, moisture handling)
• label claim strategy that doesn’t account for measurement uncertainty and stability drift
• simple label math errors (units, totals, rounding)

In Alberta, this can become a commercial issue quickly because AGLC is the province’s sole wholesaler for retail products, and suppliers’ relationships with the wholesaler depend on maintaining compliant listings.

AGLC licensing and policy resources (including manuals and handbooks) are centralized at https://aglc.ca/cannabis.

The federal rule behind most potency/label failures: Canada’s 85%–115% tolerance

A significant portion of “potency audit” outcomes ultimately map back to the federal labelling accuracy tolerance in the Cannabis Regulations.

Under section 97 of the Cannabis Regulations (SOR/2018-144), it is generally non-compliant if:

• when a displayed quantity of THC or CBD exceeds 5 mg, the product contains less than 85% or more than 115% of that displayed quantity.

Official source: https://laws-lois.justice.gc.ca/eng/regulations/SOR-2018-144/section-97.html

Two important implications for compliance teams:

1) This is a tolerance tied to what you display on the label (and how you display it).

2) Even if your product is “safe” and free of contaminants, a potency mismatch can still be a regulatory failure.

What the label must say (and where errors commonly happen)

Health Canada’s packaging and labelling guidance provides a practical map of required elements, including:

• lot number
• packaging date
• standardized symbol
• health warning messaging
• quantity of total THC and total CBD (in mg/g or mg/unit, as applicable)

Official guide: https://www.canada.ca/en/health-canada/services/cannabis-regulations-licensed-producers/packaging-labelling-guide-cannabis-products.html

Where potency audits often expose labelling weaknesses:

• Wrong units (mg/g vs % vs mg/unit) or inconsistent units across panels
• Incorrect totals (e.g., per unit correct but per package total wrong)
• Rounding and truncation that push a value outside tolerance
• Lot number mismatch between packaging and COA
• Using outdated COAs after process, formulation, or packaging changes

AGLC sampling realities: why “we tested it” isn’t enough

AGLC’s sampling and testing program (as described in public reporting) is significant because it tests products as sold, not as you intended them to be.

That creates additional risk factors:

• time in market (THC can shift as cannabinoids degrade or convert)
• storage conditions across distribution and retail
• batch heterogeneity (a single jar or pre-roll multipack may not represent the mean)

For suppliers, the operational takeaway is simple: you need a program that is resilient to an unannounced “mystery shopper” lab pull.

Common failures AGLC’s potency audit tends to uncover (and how to fix them)

The patterns below match what Alberta suppliers and labs have been discussing publicly: potency variance and labelling issues, not contamination, are the recurring theme.

1) Aggressive THC label claims with no “uncertainty budget”

Failure mode: Marketing pushes a high THC claim close to the upper edge of what the lot can reliably support. A post-market test comes in lower, and the product falls outside the tolerance.

How to fix:

• Build a label claim policy that sets “guardrails” below the expected mean.
• Require a documented measurement uncertainty (MU) rationale from the lab method.
• Set internal rules for rounding (consistent and conservative).

2) COA validation that stops at the summary page

Failure mode: Teams review only headline numbers. They don’t assess sampling approach, moisture basis, chromatographic method, or conversion assumptions.

How to fix:

• Implement a lot-level COA verification SOP that includes:
• method name/version
• instrumentation (HPLC/UPLC, etc.)
• sample prep and homogenization notes
• LOQ/LOD where relevant
• uncertainty statement, if provided
• Require a COA authentication step (direct-from-lab PDF, hash/QR verification, or lab portal confirmation).

3) “Total THC” math and conversion assumptions aren’t standardized internally

Failure mode: Different teams (or different labs) use different conventions for calculating “total THC,” especially around acidic cannabinoids.

How to fix:

• Maintain a single internal “potency math” standard, and align it with the federal concepts of total THC and label display.
• Ensure your lab and QA team are aligned on decarboxylation/conversion conventions used for reporting.

Even when the science is correct, inconsistency across batches can create apparent label drift.

4) Weak traceability between packaged lot and tested lot

Failure mode: The lot number on the label doesn’t match the COA lot identifier or internal batch record. During an audit response, the supplier can’t quickly prove which COA supports which shipped lot.

How to fix:

• Enforce one-to-one traceability between:
• cultivation/production batch
• processing lot
• packaging lot
• COA identifiers
• Run monthly reconciliation between ERP, packaging print files, and COA metadata.

5) Stability drift isn’t incorporated into label substantiation

Failure mode: A product passes release testing but drifts by the time it’s sampled at retail.

How to fix:

• Establish a real-time stability program for high-risk formats.
• Add “time-in-market” guardrails (e.g., shorter internal shelf-life triggers for high-THC flower lots).
• Validate packaging choices and storage statements.

6) Edible/unit variability issues (especially where per-unit limits matter)

Failure mode: Per-unit THC varies across pieces/pouches, increasing the chance that a sampled unit exceeds the label or regulatory cap.

How to fix:

• Tighten mixing and dosing validation (process capability metrics).
• Add in-process controls and a higher sampling plan for uniformity.

Remember: Canada maintains strict THC caps by product class, including 10 mg THC per package for edibles and 1,000 mg THC per immediate container for extracts/topicals (see Health Canada composition guidance: https://www.canada.ca/en/services/health/publications/drugs-health-products/composition-requirements-cannabis-products.html).

Enforcement and commercial consequences: from corrective actions to delisting risk

A post-market potency failure can trigger escalating outcomes depending on severity and recurrence:

• Corrective action requests (CAPA expectations, relabelling, root-cause analysis)
• stop-sale / inventory quarantine
• recall (often used in Canada for mislabelling)
• wholesale listing consequences including potential delisting pressure for repeat issues

On the federal side, Health Canada’s compliance toolkit includes warning letters, stopping sale, seizure/detention, and other escalated actions as described in its compliance and enforcement policy and inspection reporting.

• Compliance and enforcement policy: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/laws-regulations/compliance-enforcement-policy-cannabis-act.html
• Inspection data summaries (ongoing reporting): https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/research-data/compliance-enforcement-report-cannabis-inspection-data-summary.html

In Alberta specifically, retailers also have immediate operational duties during recalls/notifications. AGLC’s wholesale portal guidance for recalls notes retailers should remove recalled products from shelves and clearly identify them as recalled.

• Alberta wholesale recalls/notifications guidance (retailer-facing): https://retail-dev02.albertacannabis.org/Support/Recalls-and-Notifications

What retailers can do: reduce onboarding risk for “aggressive THC” SKUs

Retailers in Alberta aren’t the party generating labels, but they still absorb reputational and operational fallout when a product is pulled.

If you’re a retailer onboarding new SKUs—especially those with headline THC claims—consider adding a potency-focused intake gate.

Retailer intake questionnaire (labs, methods, COA authentication)

Use these questions as a standard pre-listing or pre-purchase checklist.

COA integrity and traceability

• Provide the COA directly from the lab (PDF or portal link). How do we verify authenticity?
• What is the exact lot number on the COA, and how does it map to the packaged lot number?
• What is the test date relative to packaging date?

Method and assumptions

• What analytical method was used for potency (e.g., HPLC/UPLC)? What is the method version?
• Does the lab report total THC/total CBD and how are totals calculated?
• How does the lab handle moisture basis for flower (and is it consistent lot to lot)?

Uncertainty and claim strategy

• Does the lab provide an estimate of measurement uncertainty?
• What internal rule does the supplier use to set the label claim relative to the lot mean?

Ongoing monitoring

• Does the supplier conduct retain sample re-testing during shelf life?
• What is the supplier’s CAPA process if a post-market result differs materially from release testing?

Retailers can also require a written commitment that the supplier will notify them if any lots become subject to corrective action, stop-sale, or recall.

The “Potency Truth” checklist for LPs/brands selling into Alberta

Below is a practical, audit-ready checklist you can embed into your QA program.

Potency Truth checklist (supplier/brand edition)

1) Governance

• Written policy for label claim setting (including rounding rules)
• Defined “do not exceed” thresholds for marketing-driven claims
• Named owner (QA/QAP or compliance lead) accountable for potency label substantiation

2) Lot definition and sampling

• Documented lot/batch definition rules
• Homogenization and sampling SOPs appropriate to product format
• Retain samples stored under controlled conditions for re-test

3) Laboratory qualification

• Lab accreditation status and scope (prefer ISO/IEC 17025 where applicable)
• Method suitability evidence for each product type
• Documented process for lab changes, method changes, and out-of-trend results

4) COA verification

• COA authentication (direct-from-lab, portal verification, or equivalent)
• Cross-check lot number, packaging date, units, totals, and math
• Secondary review by QA prior to printing or releasing labels

5) Stability and drift controls

• Stability study plan by format (highest risk formats first)
• Storage statement validated, not assumed
• Time-in-market monitoring and triggers for re-test

6) Audit response readiness

• 24–48 hour “audit pack” capability: batch records, COAs, label proofs, traceability map
• CAPA templates pre-built for potency variance scenarios
• Retail communication SOP for stop-sale/recall events

Consumer rules: why potency accuracy matters for Albertans

Even though this post is aimed at operators, potency accuracy directly affects consumer decision-making and safe use.

Key Canada-wide baselines include:

• Adults may possess up to 30 g of dried product (or equivalent) in public (Government of Canada overview: https://www.justice.gc.ca/eng/cj-jp/cannabis/).
• Adults of legal age can grow up to 4 plants per household (Health Canada consumer guidance: https://www.canada.ca/en/health-canada/services/drugs-medication/cannabis/personal-use/growing-cannabis-home-safely.html).

In Alberta, the legal age is 18+ and retail is privately operated under AGLC licensing.

When labels overstate potency, consumers may pay more for less-than-advertised strength. When labels understate potency (or unit variability is high), consumers can unintentionally consume more THC than intended—raising impairment and adverse reaction risks.

2026 outlook: expect more random sampling, tighter substantiation, and retailer pressure

Nothing in the public trend line suggests Alberta is slowing down. If anything, 2025’s emphasis on potency variance and labelling infractions signals that AGLC’s random sampling and corrective action expectations will continue—and that repeat offenders should expect escalating commercial consequences, including heightened scrutiny in wholesale relationships.

Retailers will also likely become more selective, requesting method details and stronger COA verification—especially for products with aggressive THC positioning.

Key takeaways

• Potency variance and labelling are the recurring failure points; contamination is not the dominant theme.
• Federal law creates clear numeric risk: 85%–115% tolerance (for displayed THC/CBD quantities above 5 mg).
• “Potency truth” requires more than a COA—it requires claim strategy + uncertainty handling + traceability + stability monitoring.
• Retailers can materially reduce risk by standardizing an intake questionnaire and insisting on COA authentication and method transparency.

Next step: operationalize your Alberta compliance program

If you want help turning this into SOPs, intake forms, and an audit-ready evidence binder, use https://www.cannabisregulations.ai/ to:

• track Alberta and federal rule updates
• build compliant labelling and COA workflows
• standardize retailer intake and supplier QA questionnaires
• prepare for inspections, random sampling, and corrective action demands

Use CannabisRegulations.ai to stay ahead of the next AGLC THC potency audit 2025 wave—and keep your listings, brands, and stores protected.